Login
DELCATH SYSTEMS, INC. logo

DELCATH SYSTEMS, INC.

delcath.com

What Do They Do?

Sells drug-and-device systems for delivering chemotherapy to the liver to hospitals and treating centers caring for patients with liver cancers.

How Do They Make Money?

Hospitals and treating centers buy HEPZATO directly; Delcath counts consigned kits when used in a procedure and advance purchases when delivered. European hospitals buy CHEMOSAT, with sales counted when kits ship.

revenue
SegmentShareRevenue
CHEMOSAT
Sold outright
7.5%
HEPZATO KIT
Sold outright

93%

Who Are Their Customers?

Hospitals and treating centers buy HEPZATO directly under approved agreements; some hold it on consignment. Delcath sells CHEMOSAT directly to hospitals in the EU and UK.

Do Revenues Turn Into Profits?

Yes. It kept 3 cents of every revenue dollar as net income in FY2025 and turned 25 cents into free cash flow.

Operating income, FY2025
1% of revenue
▲ Turned profitable vs FY2024 (−$12.4M, −33%)
Net income, FY2025
3% of revenue
▲ Turned profitable vs FY2024 (−$26.4M, −71%)
Free cash flow, FY2025
25% of revenue
▲ Turned profitable vs FY2024 (−$19.2M, −52%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +71%
vs $20.6M in Q3 FY2025
Net income
▲ +738%
vs $830K in Q3 FY2025
HEPZATO KIT share of revenue vs 93.6% in Q3 FY2025
  • Nov 9, 2026 Raises 2026 revenue guidance The outlook puts total HEPZATO KIT and CHEMOSAT revenue at $115 million to $117 million.

Growing. Revenue grew 24.0x in 4 years, from $3.6M in FY2021 to $85.2M in FY2025, about 121% a year.

HEPZATO reaches the U.S. market HEPZATO moved from an unapproved U.S. product candidate to an FDA-approved treatment sold in the United States for eligible adults with metastatic uveal melanoma.

Broader clinical program The older report described plans to study HEPZATO in colorectal and bile-duct cancers; the latest report also describes a breast-cancer trial, broadening its clinical program.

Revenue over time
CHEMOSAT HEPZATO KIT
$100M$50M$0

Who Do They Compete With?

Competes with Immunocore Holdings, Boston Scientific, Medtronic, Merit Medical Systems, Varian Medical Systems, Sirtex Medical, AngioDynamics, IDEAYA Biosciences, and Replimune Group

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support